BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that ...

Myriad Genetics has a 12-month low of $7.35 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price lowered by Scotiabank from $24.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...

SALT LAKE CITY - Myriad Genetics, Inc. (NASDAQ: MYGN), a company specializing in molecular diagnostics and precision medicine with annual revenue of $837.6 million, has named Brian Donnelly as its ...